RxDoctor Payments Data

Kimberly Butler

Psychiatric/Mental Health · Bend, ORNPI 1578934535

Payments from drug & device makers

$936in general payments, 2019–2025

Across 22 payments — averaging $42.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$199
  • Otsuka America Pharmaceutical, Inc.$180
  • Johnson & Johnson$125
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • AbbVie$103
  • Sunovion Pharmaceuticals Inc.$92
  • plus $112 from 2 others

What the payments were for

  • Food & beverage$936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$936 in reported general payments places this provider in the 80th percentile of 540 psychiatric/mental health providers in Oregon.

See all psychiatric/mental health providers in Oregon

Medicare billing

Part B allowed, 2024
$15,841
Medicare patients
26
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$16,821
Duloxetine Hcl52$3,286
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$2,733
Buspirone Hcl47$1,871
Bupropion XlBupropion Hcl66$1,847
Methylphenidate ErMethylphenidate Hcl11$1,566
Aripiprazole13$1,441
Modafinil14$1,241
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,085
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$1,072
Sertraline Hcl36$1,000
Zolpidem Tartrate ErZolpidem Tartrate26$947
Mirtazapine40$866
Clonazepam91$704
Lamotrigine43$639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$180$16,82112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 540 psychiatric/mental health providers in Oregon.

Other psychiatric/mental health in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →